1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 158,00 | 161,00 | 11:43 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.01. | BELITE BIO, INC - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 28.01. | H.C. Wainwright reiterates Buy rating on Belite Bio stock with $185 target | 2 | Investing.com | ||
| 27.01. | Belite Bio completes enrollment in phase 2/3 STGD1 drug trial | 2 | Investing.com | ||
| 27.01. | BELITE BIO, INC - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 26.01. | BofA Securities initiates coverage on Belite Bio stock with Buy rating | 4 | Investing.com | ||
| 16.01. | Cantor Fitzgerald reiterates Overweight rating on Belite Bio stock | 1 | Investing.com | ||
| 06.01. | Morgan Stanley initiates Belite Bio stock with Overweight rating, $191 target | 2 | Investing.com | ||
| BELITE BIO Aktie jetzt für 0€ handeln | |||||
| 03.12.25 | Belite Bio stock price target raised to $187 from $132 at Benchmark | 3 | Investing.com | ||
| 02.12.25 | Mizuho upgrades Belite Bio stock to Outperform on positive trial data | 1 | Investing.com | ||
| 02.12.25 | Mizuho stuft Belite Bio nach positiven Studiendaten auf 'Outperform' hoch | 10 | Investing.com Deutsch | ||
| 02.12.25 | Belite Bio prices 2.27M ADSs at $154.00 to raise $350M in public offering | 2 | Seeking Alpha | ||
| 02.12.25 | Belite Bio prices public offering of ADSs at $154 each | 1 | Investing.com | ||
| 02.12.25 | Belite Bio, Inc: Belite Bio Announces Pricing of $350.0 Million Underwritten Public Offering of American Depositary Shares | 1 | GlobeNewswire (USA) | ||
| 02.12.25 | Why Belite Bio Stock Soared on Monday | 1 | The Motley Fool | ||
| 01.12.25 | Belite Bio kündigt Kapitalerhöhung an - Aktie gibt nach | 2 | Investing.com Deutsch | ||
| 01.12.25 | Belite Bio launches public offering of American Depositary Shares | 1 | Investing.com | ||
| 01.12.25 | Belite Bio announces proposed underwritten public offering of ADSs | 1 | Seeking Alpha | ||
| 01.12.25 | Belite Bio, Inc: Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares | 1 | GlobeNewswire (USA) | ||
| 01.12.25 | Belite continues ascent as Stargardt drug hits mark in late-stage trial | 2 | BioPharma Dive | ||
| 01.12.25 | Belite Bio Reports Landmark Phase 3 Success For Tinlarebant In Stargardt Disease | - | RTTNews |
1 2 3 Weiter >>
59 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SANGAMO THERAPEUTICS | 0,339 | +1,14 % | Weekly Buzz: ATYR To Meet With FDA, SGMO Aces Fabry Study, AQST's Anaphylm Gets Rejected | PETAH TIKVA (dpa-AFX) - This week's biotech landscape witnessed key FDA meetings being scheduled, IND clearances, complete response letters, sale of oncology assets and clinical trial data readouts... ► Artikel lesen | |
| ABIVAX | 98,30 | -0,30 % | ABIVAX Société Anonyme (ABVX): A Bull Case Theory | ||
| GERON | 1,300 | +0,78 % | Geron Corporation Provides 2026 Financial Guidance | 2026 RYTELO (imetelstat) net product revenue expected in the range of $220 to $240 million 2026 total operating expenses expected in the range of $230 to $240 million Expected top-line growth and... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 1,352 | -0,44 % | Cardiff Oncology, Inc.: Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC | - Onvansertib added to FOLFIRI/bev first-line standard of care regimen showed dose-dependent improvement in overall response rates and durability trends as measured by progression-free survival in... ► Artikel lesen | |
| ARGENX | 688,00 | -0,03 % | DEUTSCHE BANK RESEARCH stuft Argenx auf 'Hold' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Argenx nach Eckdaten für 2025 auf "Hold" mit einem Kursziel von 675 Euro belassen. Der Umsatz mit dem Medikament Vyvgart... ► Artikel lesen | |
| CYTOKINETICS | 52,50 | -0,94 % | Cytokinetics stock maintains Buy rating at B.Riley amid strong CMI market | ||
| OCULAR THERAPEUTIX | 7,700 | -0,80 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | ||
| CYTOMX THERAPEUTICS | 4,826 | +0,88 % | SD-Tipp CytomX: Was tun nach +1.438% in 10 Monaten? | Unsere Aktien-Empfehlung CytomX Therapeutics erlebt derzeit einen außergewöhnlich starken Kursverlauf. Innerhalb kurzer Zeit hat sich das Papier von einem lange übersehenen Small-Cap-Titel zu einem... ► Artikel lesen | |
| PALISADE BIO | 1,660 | +10,67 % | Palisade Bio, Inc.: Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board | Internationally recognized leaders in inflammatory bowel disease bring deep expertise spanning ulcerative colitis, Crohn's disease, and late-stage clinical trial design Appointments strengthen Palisade... ► Artikel lesen | |
| AVID BIOSERVICES | - | - | Avid Bioservices Appoints Rich McAvoy as Chief Business Officer | Seasoned business and finance leader brings disciplined growth mindset to support Avid's next phase of expansion and client executionTUSTIN, Calif., Jan. 15, 2026 /PRNewswire/ -- Avid Bioservices... ► Artikel lesen | |
| BIOAGE LABS | 16,600 | -5,68 % | AKTIONÄR-Tipp BioAge Labs wird entdeckt: 272 Prozent Kurspotenzial! | Der Megatrend Longevity hat nun auch die Aktie von BioAge Labs erfasst. Ausgehend vom 52-Wochen-Tief bei 2,88 Dollar konnte sich der Titel auf aktuell 19,60 Dollar zuletzt vervielfachen. Und die Analysten... ► Artikel lesen | |
| SPERO THERAPEUTICS | 2,030 | 0,00 % | Anterix Inc.: Anterix Appoints Ross Spero as Chief Product Officer | WOODLAND PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Anterix, Inc. (NASDAQ: ATEX) today announced the appointment of Ross Spero as Chief Product Officer. Spero will lead Anterix's product development... ► Artikel lesen | |
| PROTALIX BIOTHERAPEUTICS | 2,420 | -0,82 % | Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio (pegunigalsidase alfa) in the EU | Committee
for
Medicinal
Products
for
Human
Use
(CHMP)
issues
a
positive
opinion following re-examination, which
will
be reviewed by
the... ► Artikel lesen | |
| SYNDAX PHARMACEUTICALS | 17,500 | -1,69 % | Syndax Pharmaceuticals, Inc.: Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | ||
| ALIGOS THERAPEUTICS | 5,400 | -12,90 % | Aligos Therapeutics, Inc. - 8-K, Current Report |
Das Unternehmen BELITE BIO INC ADR kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 158,00 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BELITE BIO INC ADR finden Sie auf Wallstreet Online.